Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 231

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 231
---
 of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. 

4. PREPAID EXPENSES AND OTHER CURRENT ASSETS 

Prepaid expenses and other current assets consisted of the following (in thousands): JUNE 30,2025DECEMBER 31,2024Prepaid external R&D costs$14,817 $15,748 Prepaid external manufacturing costs1,959 5,545 Prepaid sales tax91 121 Prepaid insurance1,431 651 Prepaid subscriptions1,434 960 Interest and dividend receivable1,923 1,714 Prepaid legal and consultants2,599 31 Other2,523 1,450 Total prepaid expenses and other current assets$26,777 $26,220 

11

5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES 

Accrued expenses and other current liabilities consisted of the following (in thousands): JUNE 30,2025DECEMBER 31,2024Accrued external R&D costs$6,278 $5,139 Accrued external manufacturing costs2,126 4,308 Accrued compensation and benefits8,165 10,130 Accrued legal and consulting fees3,046 877 Other349 416 Total accrued expenses and other current liabilities$19,964 $20,870 

Accrued compensation and benefits consisted primarily of accrued payroll, accrued severance and accrued vacation.

6. STOCKHOLDERS' EQUITY

As of June 30, 2025, the Company’s amended and restated certificate of incorporation authorized the Company to issue 200,000,000 shares of common stock at a par value of $0.0001 per share.On January 8, 2024, the Company closed an underwritten public offering in which 4,025,000 shares of common stock were issued and sold, which included 525,000 shares of common stock issued and sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $40.00 per share. The aggregate net proceeds to the Company from the public offering were approximately $151.1 million, after deducting underwriting discount, commissions and offering expenses. Stockholder Rights PlanOn April 9, 2025, the Board declared a dividend of one right (“